ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2019

Sep 25, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2019-09-20

Reporting Person: Anzalone Christopher Richard (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-09-20	Common Stock	M	4250	$5.10	Acquired	2146153	Direct
2019-09-20	Common Stock	S	4250	$29.00	Disposed	2141903	Direct
2019-09-23	Common Stock	M	41755	$5.10	Acquired	2183658	Direct
2019-09-23	Common Stock	S	41755	$29.04	Disposed	2141903	Direct
2019-09-24	Common Stock	M	66645	$5.10	Acquired	2208548	Direct
2019-09-24	Common Stock	S	53972	$28.00	Disposed	2154576	Direct
2019-09-24	Common Stock	S	12673	$29.04	Disposed	2141903	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-09-20	Stock Option (right to buy)	$5.10	M	4250	Disposed	2019-10-08	Common Stock (4250)	Direct
2019-09-23	Stock Option (right to buy)	$5.10	M	41755	Disposed	2019-10-08	Common Stock (41755)	Direct
2019-09-24	Stock Option (right to buy)	$5.10	M	66645	Disposed	2019-10-08	Common Stock (66645)	Direct

Footnotes

F1: This option exercise was completed as the underlying option was due to expire in October 2019.

F2: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.10, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F3: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.00 to $28.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F4: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.10, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.

F5: Includes a total of 933,333 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole.

F6: Represents first vesting date. Option vested over two years from date of grant.